Carlos Martinez, MD
Pulmonary Disease · Homestead, FLNPI 1003874561
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,656 of the $2,326 with a category attached, or 71.2%. Chiesi USA, Inc. accounts for 84.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,026 and has fallen 96.9% since, to $63 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 17 payments — averaging $136.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$2K
- Eisai Inc.$109
- Gilead$72
- Otsuka America Pharmaceutical, Inc.$64
- Zimvie Inc.$35
- Abbott$22
- plus $53 from 3 others
Across 130 payments — averaging $70,772 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7.4M
- Sanofi US Services Inc.$635K
- AbbVie$592K
- Chiesi USA, Inc.$372K
- Amgen$186K
What the payments were for
- Travel & lodging$1,65671%
- Food & beverage$67129%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 3 | $1,972 |
| Eisai Inc. | 3 | $109 |
| Gilead | 3 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Zimvie Inc. | 1 | $35 |
| Abbott | 1 | $22 |
| PBG Puerto Rico LLC | 1 | $20 |
| GSK | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
How this compares
$2,326 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Homestead
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.